Detalhe da pesquisa
1.
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
BMC Med
; 21(1): 87, 2023 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882736
2.
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Eur Arch Otorhinolaryngol
; 276(2): 541-550, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30523411
3.
Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Reprod Biomed Online
; 35(4): 468-474, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28652099
4.
Morbidity-mortality conference for adverse events associated with totally implanted venous access for cancer chemotherapy.
Support Care Cancer
; 24(4): 1857-63, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26454864
5.
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
Breast
; 56: 18-25, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33561617
6.
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.
Front Oncol
; 9: 575, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355134
7.
The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
BMJ Open
; 9(2): e023568, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796119
8.
Totally implanted venous access-associated adverse events in oncology: Results from a prospective 1-year surveillance programme.
Bull Cancer
; 105(11): 1003-1011, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30322697